{"id":"W4367302706","doi":"10.1212/wnl.0000000000202314","title":"Phase 1/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)","year":2023,"lang":"en","type":"article","venue":"Neurology","topic":"Ophthalmology and Eye Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Placebo; Tolerability; Diplopia; Internal medicine; Antagonist; Clinical endpoint; Gastroenterology; Randomized controlled trial; Surgery; Adverse effect; Receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003433395,0.0002780764,0.0006376372,0.0002739808,0.0001169711,0.000008272713,0.0003158767,0.0001969294,0.0001496761],"category_scores_gemma":[0.0005041806,0.0001902617,0.00007982134,0.000830186,0.0002895809,0.00005914099,0.0001737166,0.000712508,0.0002377632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001255447,"about_ca_system_score_gemma":0.0001281827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000143391,"about_ca_topic_score_gemma":0.00007950129,"domain_scores_codex":[0.9971903,0.0006183938,0.000662091,0.0006832996,0.000322142,0.0005237691],"domain_scores_gemma":[0.9983563,0.000365649,0.0001781686,0.0006469015,0.0001666448,0.0002862714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03412099,0.01598755,0.9468133,0.00003251577,0.0001047121,0.000523718,0.0004963342,0.00001442627,0.0001331623,0.000007181022,0.001280392,0.0004857212],"study_design_scores_gemma":[0.02216776,0.0549836,0.9209223,0.00001169819,0.0001005694,0.000004515674,0.000130948,0.00005849753,0.000004009816,0.00001640229,0.001442979,0.0001566935],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994431,0.00004668335,0.000002251876,0.002812294,0.0008242829,0.001576973,0.0001236451,0.00008047732,0.0001023619],"genre_scores_gemma":[0.9969299,0.00003871151,0.00000659505,0.002370354,0.0001009962,0.00006279257,0.0003663542,0.00004617294,0.00007812822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03899606,"threshold_uncertainty_score":0.7758647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02348927210802151,"score_gpt":0.35168030947685,"score_spread":0.3281910373688285,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}